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Objective - To assess the changes in the medicamen-
tous treatment of elderly patients hospitalized with acute
myocardial infarction occurring over an 8-year period.
Methods - We retrospectively analyzed 379 patients
above the age of 65 years with acute myocardial infarcti-
on who were admitted to the coronary unit of a university-
affiliated hospital from 1990 to 1997. The patients were di-
vided into 2 groups, according to the period of time of hos-
pital admission as follows: group 1 - from 1990 to 1993;
and group 2 - from 1994 to 1997.
Results - The use of beta-blockers (40.8% x 75.2%,
p<0.0001) and angiotensin-converting enzyme inhibi-
tors (42% x 59.5%, p=0.001) was significantly greater in
group 2, while the use of calcium antagonists (42% x
18.5%, p<0.0001) and general antiarrhythmic drugs
(19.1% x 10.8%, p=0.03) was significantly lower. No sig-
nificant difference was observed in regard to the use of
acetylsalicylic acid, thrombolytic agents, nitrate, and di-
gitalis in the period studied. The length of hospitalization
was shorter in group 2 (13.4±8.9 days x 10.5±7.5 days,
p<0.001). The in-hospital mortality was 35.7% in group 1
and 26.6% in group 2 (p=0.07).
Conclusion - Significant changes were observed in
the treatment of elderly patients with acute myocardial in-
farction, with a greater use of beta-blockers and angio-
tensin-converting enzyme inhibitors and a lower use of
calcium antagonists and antiarrhythmic drugs in group 2.
The length of hospitalization and the mortality rate were
also lower in group 2, even though the reduction in morta-
lity was not statistically significant.
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Cardiovascular disease is the major cause of mortality in
the population above the age of 65 years 1. In Brazil, according
to the Pan-American Health Organization and the World
Health Organization (1994), cardiovascular disease accounts
for 50.3% of the deaths in the population above the age of 50
years, acute myocardial infarction being its major cause 2.
The treatment of acute myocardial infarction has under-
gone significant changes over the past 30 years, with a pro-
gressive decrease in mortality from 30% to 4 to 7% in properly
treated patients 3-6. In elderly patients, however, mortality still
remains elevated, ranging from 17.5% to 41% 7-11.
The factors accounting for the higher mortality and
morbidity of elderly patients have not been totally defined.
The intrinsic cardiovascular alterations related to the aging
process are believed to leave the elderly with a lower func-
tional reserve to deal with the complications caused by acu-
te myocardial infarction. In addition, a higher number of as-
sociated diseases, of diagnostic difficulties, and of differen-
ces in the therapeutical approach exist 12-15.
In the elderly, a trend in a reduced use of drugs like be-
ta-blockers, acetylsalicylic acid, and thrombolytic agents
with proved efficacy in treating myocardial infarction has
been shown in several studies that assessed the use of
these medications in clinical practice 16-21.
Several factors have been related to this reduced use,
such as the fear of adverse reactions, the presence of co-
morbidities increasing the contraindications, the diagnostic
difficulties that delay treatment onset, and also the fact that
the elderly have been excluded from or little represented in
most studies that assess the drugs used in the treatment of
acute myocardial infarction 22,23.
Therefore, this study aimed to assess the changes in
the therapeutical approach for elderly patients admitted to a
university-affiliated hospital in the acute phase of myocar-
dial infarction during an 8-year period.
Methods
We retrospectively studied 379 patients above the age
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of 65 years in the acute phase of myocardial infarction, who
were consecutively admitted to the coronary unit of the
Hospital São Paulo affiliated with the Escola Paulista de Me-
dicina of the Universidade Federal de São Paulo for a period
of 8 years (from 1990 to 1997). Their ages ranged from 65 to
94 (mean of 73.5) years. Most patients (55.7%) were males.
The medical records of all patients were carefully reviewed,
and the criterion used to diagnose myocardial infarction
was the presence of at least 2 of the following findings: sug-
gestive clinical picture, electrocardiographic and enzymatic
alterations. When necessary, we used additional data deri-
ved from the radioisotopic study with technetium pyro-
phosphate, echocardiography, and autopsy. No patient was
excluded from the study.
The patients were divided into 2 groups according to
the time of hospitalization, and we assessed changes in
drug prescription and in clinical evolution during the
period analyzed. Group 1 consisted of 157 patients with a
mean age of 73.3±7.03 years (ranging from 65 to 94) who
were consecutively hospitalized from 1990 to 1993; group
2 consisted of 222 patients with a mean age of 73.8±6.51
years (ranging from 65 to 90) who were consecutively
hospitalized from 1994 to 1997 (p=0.46). The groups
showed no statistically significant differences in regard to
age, sex, functional class at hospital admission, infarct
location, antecedents of arterial hypertension, diabetes
mellitus, previous heart disease, and previous infarction.
The only difference observed was the higher prevalence
of non-Q-wave infarction in group 2 (tab. I).
The numerical variables were analyzed using the Stu-
dent  t  test for comparison between the groups. The
analysis of the qualitative variables was performed with the
chi-square test (X2), and in the cases where it could not be
used, the Fisher exact test was performed. The statistical
significance level adopted was 5% (p<0.05).
Results
The major drugs used in the elderly patients during
hospitalization are shown in table II. The patients in group
2, who were more recently treated, received proportionally
more beta-blockers (40.8% x 75.2%, p<0.0001) and angioten-
sin-converting enzyme inhibitors (42% x 59.5%, p=0.001)
than the patients in group 1. No significant difference was
observed in regard to the intravenous use of beta-blockers
between the groups (31.3% x 39.5%, p=0.311).
We also observed a significantly lower use of calcium
antagonists in group 2 (42% x 18.5%, p<0.0001). In regard to
the type of calcium antagonist used, nifedipine was used
significantly less (42.4% x 12.2%, p<0.002) and diltiazem
significantly more in group 2 (57.6% x 85.4%, p=0.005).
The use of antiarrhythmic drugs was also significantly
lower in group 2, both in the prophylactic (10.8% x 1.3%,
p<0.001) and global (therapeutic and prophylactic) (19.1% x
10.8%, p=0.03) forms.
No significant statistical difference between the groups
was observed in the use of acetylsalicylic acid (87.3% x
92.3%, p=0.14), thrombolytic agents (43.9% x 43.7%,
p=0.95), nitrate (82.8% x 86.5%, p=0.4), and digitalis (26.1% x
18.9%, p=0.12).
The mean length of hospitalization was significantly
lower in group 2 (13.4±8.9 days x 10.5±7.5 days, p=0.0007),
which also had a lower in-hospital mortality, even though
this difference has not reached statistical significance
(35.7% x 26.6%, p=0.07).
Discussion
Age is an independent predictor of mortality after acu-
te myocardial infarction, which makes the elderly patients a
high-risk group for complications and mortality 24,25. There-
fore, they have the highest potential for therapeutic benefit
Table I – Clinical and demographic characteristics of 379 elderly
patients hospitalized with myocardial infarction from 1990 to 1997
Total Group 1 Group 2
Variables (1990-93) (1994-97) p
n = 379 n = 157 n = 222
Sex
Male 211 (55.7%) 84 (53.5%) 127 (57.2%) 0.541
Female 168 (44.3%) 73 (46.5%) 95 (42.8%)
Functional class
Killip  I - II 316 (83.4%) 133 (84.7%) 183 (82.4%) 0.654
               III - IV 63 (16.6%) 24 (15.3%) 39 (17.6%)
Infarction location
Anterior 158 (41.7%) 69 (43.9%) 89 (40.1%) 0.519
Nonanterior 221 (58.3%) 88 (56.1%) 133 (59.9%)
Antecedents
Previous heart disease 80 (21.1%) 31 (19.7%) 49 (22.1%) 0.675
Diabetes mellitus 118 (31.1%) 54 (34.4%) 64 (28.8%) 0.298
Hypertension 232 (61.2%) 91 (57.9%) 141 (63.5%) 0.324
Previous infarction  51 (13.5%) 17 (10.8%) 34 (15.3%) 0.267
Non-Q-wave infarction 61 (16.0%) 17 (10.8%) 44 (19.8%) 0.027*
*p<0.05.
Table II- Medications used in elderly patients in the acute phase of
myocardial infarction
Total Group 1 Group 2
Medication (1990-93) (1994-97) p
n = 379 n = 157 n = 222
Acetylsalicylic acid 342 (90.2%) 137 (87.3%) 205 (92.3%) 0.14
Calcium antagonists 107 (28.2%) 66 (42%) 41 (18.5%) < 0.0001*
Nifedipine 33 (30.8%) 28 (42.4%) 5 (12.2%) 0.002*
Diltiazem 73 (68.2%) 38 (57.6%) 35 (85.4%) 0.005*
Verapamil 1 (0.9%) 0 1 (2.4%)
Antiarrhythmic drugs
Global 54 (14.2%) 30 (19.1%) 24 (10.8%) 0.03*
Prophylactic 20 (5.3%) 17 (10.8%) 3 (1.3%) < 0.001
Beta-blockers
Total 231 (60.9%) 64 (40.8%) 167 (75.2%) < 0.0001*
Intravenous 86 (37.2%) 20 (31.3%) 66 (39.5%) 0.31
Digitalis 83 (21.9%) 41 (26.1%) 42 (18.9%) 0.12
ACE inhibitor 198 (52.2%) 66 (42%) 132 (59.5%) 0.001*
Nitrate 322 (84.9%) 130 (82.8%) 192 (86.5%) 0.4
Thrombolytic agent 166 (43.8%) 69 (43.9%) 97 (43.7%) 0.95
* p<0.05; ACE- angiotensin-converting enzyme.
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resulting from the use of medication that has been proved to
reduce mortality after acute myocardial infarction, such as
beta-blockers, acetylsalicylic acid, and angiotensin-conver-
ting enzyme inhibitors. However, in clinical practice, we ob-
serve a tendency toward the lower use of these drugs in el-
derly patients.
In the present study, a retrospective 8-year analysis of
379 elderly patients hospitalized with acute myocardial in-
farction, the medicamentous treatment prescribed in the
first 4 years (group 1) was compared with that prescribed in
the last 4 years (group 2). No statistically significant diffe-
rences were observed between the 2 groups in regard to
age, sex, functional class at admission, infarct location, an-
tecedents of arterial hypertension, diabetes mellitus, pre-
vious heart disease, and previous infarction. A significant
difference was only observed in regard to the presence of
non-Q-wave infarction, which was higher in group 2. The
demographic characteristics reported as poor-prognostic
factors after acute myocardial infarction were as follows:
age >60 years, female sex, Q-wave infarction, diabetes melli-
tus, and previous infarction 26.
The prevalence of non-Q-wave acute myocardial in-
farction increases with age. Gurwitz et al 27 showed an 8.2%
rate of non-Q-wave acute myocardial infarction in patients
below the age of 55 years, 10.4% for patients between 55
and 64 years, 13.7% between 65 and 74 years, 16.7% between
75 and 84 years, and 18.4% above 85 years. Data from the
Framingham Study have shown that in-hospital mortality
due to non-Q-wave acute myocardial infarction is lower
than that observed in transmural acute myocardial infarc-
tion; long-term mortality, however, is similar because of the
high risk of reinfarction in these patients 28.
Significant differences in drug prescription were ob-
served in the periods analyzed. A significant increase in the
use of beta-blockers was observed in the last 4 years analy-
zed. The global rate of use of these drugs increased from
40.8% in group 1 to 75.2% in group 2 (p<0.0001). Comparing
these results with data in the literature, the rate of beta-
blocker use observed in the last years studied is very high.
In a retrospective study of 369 patients with acute myocar-
dial infarction, Brandt et al 29 observed that only 27.7% of
the elderly received beta-blockers during hospitalization. It
seems that a certain fear exists in regard to the intravenous
use of beta-blockers, because the awaited proportional in-
crease in their global use did not occur (31.3% x 39.5%,
p=NS). The use of beta-blockers has been recommended in
the acute phase of acute myocardial infarction for all pa-
tients when contraindications do not exist 30-31. Studies as-
sessing the use of these drugs in acute myocardial infarction
have shown a more significant reduction in mortality in el-
derly patients 32-36.
The use of angiotensin-converting enzyme inhibitors
was also higher in group 2, which was more recently treated
(42% x 59.5%, p=0.001). Some studies have shown a reduc-
tion in mortality with the use of these drugs in acute myocar-
dial infarction, mainly in the presence of infarction of the
anterior wall and signs of heart failure 37,38. The SAVE trial
(1992) showed a 13% reduction in mortality in patients aged
from 56 to 64 years and a 25% reduction in mortality in pa-
tients above 65 years 39. Malone et al 40, in a study that as-
sessed the differences in treatment after acute myocardial
infarction according to age, reported that the use of angio-
tensin-converting enzyme inhibitors increased with age,
from 17% in younger patients to around 30% in elderly
patients, due to the higher frequency of heart failure in the
latter patients.
In regard to calcium antagonists, their use significan-
tly dropped from 42% to 18.5% in the last 4 years studied
(p<0.0001). A change in the type of calcium antagonist
prescribed during hospitalization was observed. The use of
nifedipine was significantly lower, while a proportional
increase in the use of diltiazem, usually indicated as a subs-
titute for the beta-blocker or after transluminal coronary an-
gioplasty, was observed. The studies assessing the use of
calcium antagonists in the treatment of acute myocardial in-
farction showed no benefits, and, in some cases, even
showed a deleterious effect 41-44. The ACC/AHA Guidelines
for the Management of Patients with Acute Myocardial In-
farction and the guidelines of the Brazilian Society of Car-
diology (SBC) do not recommend the routine use of those
drugs after acute myocardial infarction. This is due to the
fact that, even in the case of non-Q-wave acute myocardial
infarction, no evidence exists that calcium antagonists, es-
pecially diltiazem and verapamil, are more beneficial than
beta-blockers are 30,31,45. Short-acting nifedipine is contrain-
dicated in the acute phase of myocardial infarction because
it has a negative inotropic effect and causes reflex sympa-
thetic activation.
The use of antiarrhythmic drugs in acute myocardial
infarction, especially lidocaine, underwent significant chan-
ges in the past decade, prior to which it was routinely used
for ventricular fibrillation prophylaxis. The more recent re-
commendations, however, limit its use to the treatment of
potentially fatal arrhythmias. A meta-analysis published in
1988 showed a trend in higher mortality in the group recei-
ving prophylactic lidocaine, despite the 33% reduction in
the ventricular fibrillation rate 46. In our study, the more re-
cently treated group used significantly lower amounts of
antiarrhythmic drugs during hospitalization, both in the
prophylactic and global forms (10.8% x 1.3%, p<0.001 and
19.1% x 10.8%, p=0.03, respectively).
We observed no difference between the groups in re-
gard to the use of acetylsalicylic acid, thrombolytic drugs,
nitrate, and digitalis. The mean global rate of use of acetyl-
salicylic acid was 90.2%. We considered the rate of use of
acetylsalicylic acid in our study to be adequate, because,
despite the recommendation for this drug to be routinely
used in acute myocardial infarction due to its effect on mor-
tality reduction at a low cost and good tolerability, some
studies still show its lower use in elderly patients. In a re-
cent analysis of 5,490 patients above 65 years of age hospi-
talized with acute myocardial infarction, only 76% of the
patients with no contraindications received acetylsalicylic
acid during hospitalization 47.
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The mean global rate of use of thrombolytic drugs in
our study was 43.8%. The use of these drugs in elderly
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The mean global rate of use of nitrate in the present
study was high (84.9%). Nitrate has been recommended to
improve persistent ischemia, heart failure, and hyperten-
sion after acute myocardial infarction, because no signifi-
cant reduction in mortality occurred with its routine use in
acute myocardial infarction 30,31,37.
Only 21.9% of the patients received digitalis during
hospitalization. The use of digitalis in acute myocardial in-
farction has been recommended for select patients with su-
praventricular tachyarrhythmias associated with heart fai-
lure or heart failure refractory to the use of angiotensin-con-
verting enzyme inhibitors and diuretics 30.
In regard to length of hospitalization, a significant diffe-
rence was observed between the groups (group 2 had a
shorter length of hospitalization). This reduction in the length
of hospitalization may be related to the more adequate
therapeutic regimen used in that group; however, it may also
have resulted from the changes in our service in the past few
years, which may have sped up the performance of tests
and procedures, allowing earlier hospital discharge.
A not significant tendency toward lower mortality was
observed in group 2 (35.7% and 26.6%, p=0.07). The size of
the sample and the limitations of a retrospective study have
limited the analysis of mortality, which remained undoub-
tedly high in the elderly patients.
The changes in the treatment of elderly patients with
acute myocardial infarction observed in this study resulted
from the standardization of the management adopted at the
coronary unit of the Hospital São Paulo based on the re-
sults of multicenter studies and on the recommendations of
the ACC/AHA Task Force and the guidelines of the Brazi-
lian Society of Cardiology 30,31. We observed that, despite
the correct use of the drugs recommended by the national
and international guidelines, mortality in the elderly remains
very high, suggesting that a more aggressive treatment after
acute myocardial infarction may cause a greater impact on
the improvement of ventricular function and on mortality in
this group of patients. Therefore, randomized studies asses-
sing the efficacy of therapeutic interventions are required,
especially in elderly patients older than 75 years, because
this group has been systematically excluded from most stu-
dies already performed.
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